Triptonide Effectively Inhibits Wnt/β-Catenin Signaling via C-terminal Transactivation Domain of β-catenin

Area of Science:

• Molecular Biology
• Pharmacology
• Developmental Biology

Background:

• Aberrant Wnt/β-catenin signaling is a key driver in numerous diseases, notably cancer.
• Developing effective therapeutic agents to modulate this pathway is a significant research focus.
• Triptonide, a bioactive molecule from Tripterygium wilfordii Hook F., exhibits diverse biological activities.

Purpose of the Study:

• To investigate the inhibitory effects of triptonide on canonical Wnt/β-catenin signaling.
• To explore the therapeutic potential of triptonide in disease models and cancer treatment.

Main Methods:

• Assessed triptonide's impact on Wnt/β-catenin signaling by targeting β-catenin.
• Utilized a zebrafish model to evaluate triptonide's rescue of Wnt pathway-induced developmental defects.
• Examined triptonide's effect on apoptosis in Wnt-dependent cancer cells.

Main Results:

• Triptonide effectively inhibits canonical Wnt/β-catenin signaling, likely by interacting with β-catenin's transcription domain or nuclear partners.
• Triptonide treatment rescued the 'eyeless' phenotype in zebrafish embryos caused by Wnt signaling activation.
• Triptonide demonstrated potent induction of apoptosis in Wnt-dependent cancer cells.

Conclusions:

• Triptonide is a novel inhibitor of the canonical Wnt/β-catenin pathway.
• Triptonide exhibits therapeutic promise for conditions associated with Wnt pathway dysregulation, including cancer.
• Further research into triptonide as a therapeutic agent is warranted.